Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODIN-BM: Osimertinib Brain Exposure in EGFRm NSCLC
NCT03463525Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Maximum Concentration of Percent of Injected Dose in the Whole Brain at Day 25, Maximum Concentration of Brain Standardized Uptake Value at Day 25 and 2 more. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03463525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463525.